Cargando…

Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues

In the 1990s, tumour necrosis factor-α inhibitor therapy ushered in the biologic therapy era for inflammatory bowel disease, leading to marked improvements in treatment options and patient outcomes. There are currently four tumour necrosis factor-α inhibitors approved as treatments for ulcerative co...

Descripción completa

Detalles Bibliográficos
Autores principales: Peyrin-Biroulet, Laurent, Sandborn, William J., Panaccione, Remo, Domènech, Eugeni, Pouillon, Lieven, Siegmund, Britta, Danese, Silvio, Ghosh, Subrata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669878/
https://www.ncbi.nlm.nih.gov/pubmed/34917173
http://dx.doi.org/10.1177/17562848211059954
_version_ 1784614868198883328
author Peyrin-Biroulet, Laurent
Sandborn, William J.
Panaccione, Remo
Domènech, Eugeni
Pouillon, Lieven
Siegmund, Britta
Danese, Silvio
Ghosh, Subrata
author_facet Peyrin-Biroulet, Laurent
Sandborn, William J.
Panaccione, Remo
Domènech, Eugeni
Pouillon, Lieven
Siegmund, Britta
Danese, Silvio
Ghosh, Subrata
author_sort Peyrin-Biroulet, Laurent
collection PubMed
description In the 1990s, tumour necrosis factor-α inhibitor therapy ushered in the biologic therapy era for inflammatory bowel disease, leading to marked improvements in treatment options and patient outcomes. There are currently four tumour necrosis factor-α inhibitors approved as treatments for ulcerative colitis and/or Crohn’s disease: infliximab, adalimumab, golimumab and certolizumab pegol. Despite the clear benefits of tumour necrosis factor-α inhibitors, a subset of patients with inflammatory bowel disease either do not respond, experience a loss of response after initial clinical improvement or report intolerance to anti-tumour necrosis factor-α therapy. Optimizing outcomes of these agents may be achieved through earlier intervention, the use of therapeutic drug monitoring and thoughtful switching within class. To complement these approaches, evolving predictive biomarkers may help inform and optimize clinical decision making by identifying patients who might potentially benefit from an alternative treatment strategy. This review will focus on the current use of tumour necrosis factor-α inhibitors in inflammatory bowel disease and the application of personalized medicine to improve future outcomes for all patients.
format Online
Article
Text
id pubmed-8669878
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-86698782021-12-15 Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues Peyrin-Biroulet, Laurent Sandborn, William J. Panaccione, Remo Domènech, Eugeni Pouillon, Lieven Siegmund, Britta Danese, Silvio Ghosh, Subrata Therap Adv Gastroenterol Review In the 1990s, tumour necrosis factor-α inhibitor therapy ushered in the biologic therapy era for inflammatory bowel disease, leading to marked improvements in treatment options and patient outcomes. There are currently four tumour necrosis factor-α inhibitors approved as treatments for ulcerative colitis and/or Crohn’s disease: infliximab, adalimumab, golimumab and certolizumab pegol. Despite the clear benefits of tumour necrosis factor-α inhibitors, a subset of patients with inflammatory bowel disease either do not respond, experience a loss of response after initial clinical improvement or report intolerance to anti-tumour necrosis factor-α therapy. Optimizing outcomes of these agents may be achieved through earlier intervention, the use of therapeutic drug monitoring and thoughtful switching within class. To complement these approaches, evolving predictive biomarkers may help inform and optimize clinical decision making by identifying patients who might potentially benefit from an alternative treatment strategy. This review will focus on the current use of tumour necrosis factor-α inhibitors in inflammatory bowel disease and the application of personalized medicine to improve future outcomes for all patients. SAGE Publications 2021-12-09 /pmc/articles/PMC8669878/ /pubmed/34917173 http://dx.doi.org/10.1177/17562848211059954 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution 4.0 License (https://creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Review
Peyrin-Biroulet, Laurent
Sandborn, William J.
Panaccione, Remo
Domènech, Eugeni
Pouillon, Lieven
Siegmund, Britta
Danese, Silvio
Ghosh, Subrata
Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
title Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
title_full Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
title_fullStr Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
title_full_unstemmed Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
title_short Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
title_sort tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669878/
https://www.ncbi.nlm.nih.gov/pubmed/34917173
http://dx.doi.org/10.1177/17562848211059954
work_keys_str_mv AT peyrinbirouletlaurent tumournecrosisfactorinhibitorsininflammatoryboweldiseasethestorycontinues
AT sandbornwilliamj tumournecrosisfactorinhibitorsininflammatoryboweldiseasethestorycontinues
AT panaccioneremo tumournecrosisfactorinhibitorsininflammatoryboweldiseasethestorycontinues
AT domenecheugeni tumournecrosisfactorinhibitorsininflammatoryboweldiseasethestorycontinues
AT pouillonlieven tumournecrosisfactorinhibitorsininflammatoryboweldiseasethestorycontinues
AT siegmundbritta tumournecrosisfactorinhibitorsininflammatoryboweldiseasethestorycontinues
AT danesesilvio tumournecrosisfactorinhibitorsininflammatoryboweldiseasethestorycontinues
AT ghoshsubrata tumournecrosisfactorinhibitorsininflammatoryboweldiseasethestorycontinues